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Background
Chronic migraine (CM) is a disabling type of primary
headache for which treatment with botulinum toxin type
A (BoNT-A) has proved to be effective and safe in redu-
cing headache days and headache-related disability. How-
ever, little is known about factors influencing the response
to BoNT-A. We aimed to assess which baseline factors
predicted a favorable response to BoNT-A in a sample of
patients with CM.
Materials and methods
Consecutive patients admitted to our Regional Headache
Referral Center from October 2013 to May 2015, diag-
nosed with CM and eligible for treatment with BoNT-A,
were administered a structured questionnaire investigating
baseline characteristics including smoke, alcohol abuse,
psychostimulants such as caffeine, arterial hypertension,
family history of headaches, headache features (aura, auto-
nomic symptoms, pain intensity assessed through the
Visual Analog Scale [VAS], and allodynia), disability (by
means of MIDAS and HIT-6 scores), drug abuse, depres-
sion (by means of Beck Depression Inventory [BDI]), and
anxiety (by means of Generalized Anxiety Disorder [GAD]
score). Chi-squared test and Mann-Whitney tests were
used for univariate comparisons where appropriate. Logis-
tic regression analysis was used to assess favorable
response (≥50% reduction in headache days) to BoNT-A
treatment.
Results
Thirty-nine subjects (32 women and 7 men; mean age ±
standard deviation, 48.3±9.9 years) were recruited.
Twenty-eight (71.8%) patients were on treatment with
triptans, 32 (82.1%) were on preventive treatment, and
22 (56.4%) had drug abuse. One dose of BoNT-A was
administered to 10 (25.6%) patients, 2 doses to 8
(20.5%) patients, 3 doses to 9 (23.1%) patients, 4 doses
to 3 (7.7%) patients, 5 doses to 5 (12.8%) patients, and 6
doses to 4 (10.3%) patients (Figure 1). A favorable
response was reported by 16 (41.0%) patients, while
adverse effects were reported by 12 (30.8%) patients,
with allergy, muscle tension, numbness, and trapezius
atrophy reported by 2 (5.1%) patients each, and pain,
orbicularis or frontalis muscle deficit, and headache
worsening reported by 1 (2.6%) patient each. Two
(5.1%) patients discontinued treatment with BoNT-A
because of adverse effects. Distribution of all baseline
variables did not differ between subjects with a favorable
and a non-favorable response. None of the baseline vari-
ables predicted a favorable response to BoNT-A treat-
ment or the development of adverse effects.
Conclusions
In our case series, baseline variables did not predict a
favorable effect or adverse effects from BoNT-A therapy.
Our findings suggest that further research is needed to
assess predictors of response to that therapy in order to
improve management and treatment of CM.
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